Materials-Based Approaches for Cancer Vaccination.
暂无分享,去创建一个
[1] Yusheng Liu,et al. Targeted delivery of liposomal chemoimmunotherapy for cancer treatment , 2022, Frontiers in Immunology.
[2] F. Ginhoux,et al. Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment , 2022, Cell.
[3] I. Melero,et al. Cancer vaccines: the next immunotherapy frontier , 2022, Nature Cancer.
[4] Jing Chen,et al. An in situ hydrogel-mediated chemo-immunometabolic cancer therapy , 2022, Nature Communications.
[5] Aileen W. Li,et al. A vaccine targeting resistant tumours by dual T cell plus NK cell attack , 2022, Nature.
[6] Jin Gao,et al. Engineering Bacterial Membrane Nanovesicles for Improved Therapies in Infectious Diseases and Cancer. , 2022, Advanced drug delivery reviews.
[7] Aileen W. Li,et al. Scaffold Vaccines for Generating Robust and Tunable Antibody Responses , 2022, Advanced Functional Materials.
[8] Jordan A. Stinson,et al. Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity , 2021, Nature Biomedical Engineering.
[9] B. Pulendran,et al. Designing spatial and temporal control of vaccine responses , 2021, Nature Reviews Materials.
[10] R. Brink,et al. The unique biology of germinal center B cells. , 2021, Immunity.
[11] Jianzhu Chen,et al. In situ cancer vaccination using lipidoid nanoparticles , 2021, Science Advances.
[12] B. Pulendran,et al. Emerging concepts in the science of vaccine adjuvants , 2021, Nature reviews. Drug discovery.
[13] D. Irvine,et al. Exploiting albumin as a mucosal vaccine chaperone for robust generation of lung-resident memory T cells , 2021, Science Immunology.
[14] S. Eisenbarth,et al. Dendritic Cell Regulation of T Helper Cells. , 2021, Annual review of immunology.
[15] P. Ott,et al. Personal Neoantigen Vaccines for the Treatment of Cancer , 2021 .
[16] C. Reis e Sousa,et al. Dendritic Cells Revisited. , 2021, Annual review of immunology.
[17] Rebecca L. Holden,et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma , 2021, Nature Medicine.
[18] P. Ott,et al. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines , 2021, Nature Reviews Clinical Oncology.
[19] P. Danaher,et al. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets , 2020, Nature Cancer.
[20] Aileen W. Li,et al. Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors , 2020, Nature Communications.
[21] Katie M. Campbell,et al. 304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma , 2020 .
[22] F. Ginhoux,et al. Intravenous Nanoparticle Vaccination Generates Stem-Like TCF1+ Neoantigen-Specific CD8+ T Cells , 2020, Nature immunology.
[23] J. Utikal,et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma , 2020, Nature.
[24] Aileen W. Li,et al. Single‐Shot Mesoporous Silica Rods Scaffold for Induction of Humoral Responses Against Small Antigens , 2020, Advanced Functional Materials.
[25] D. Irvine,et al. Controlling timing and location in vaccines , 2020, Advanced Drug Delivery Reviews.
[26] D. Irvine,et al. Pharmacokinetic tuning of protein–antigen fusions enhances the immunogenicity of T-cell vaccines , 2020, Nature Biomedical Engineering.
[27] C. Kojima,et al. Carboxyl-, sulfonyl-, and phosphate-terminal dendrimers as a nanoplatform with lymph node targeting. , 2020, International journal of pharmaceutics.
[28] H. Shu,et al. Innate Immune Response to Cytoplasmic DNA: Mechanisms and Diseases. , 2019, Annual review of immunology.
[29] D. Kong,et al. Dual fluorescence imaging-guided programmed delivery of doxorubicin and CpG nanoparticles to modulate tumor microenvironment for effective chemo-immunotherapy. , 2019, Biomaterials.
[30] Michele De Palma,et al. Engineering dendritic cell vaccines to improve cancer immunotherapy , 2019, Nature Communications.
[31] J. L. Santos,et al. Physical and chemical profiles of nanoparticles for lymphatic targeting. , 2019, Advanced drug delivery reviews.
[32] Jiasheng Tu,et al. Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy , 2019, Nature Communications.
[33] S. Hohaus,et al. Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial , 2019, Clinical Cancer Research.
[34] S. Thomas,et al. Material design for lymph node drug delivery , 2019, Nature Reviews Materials.
[35] Scott N. Mueller,et al. T cell and dendritic cell interactions in lymphoid organs: More than just being in the right place at the right time , 2019, Immunological reviews.
[36] M. Merad,et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination , 2019, Nature Medicine.
[37] Shuang Wang,et al. Engineering Magnetosomes for High-Performance Cancer Vaccination , 2019, ACS central science.
[38] Yu Qin,et al. Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination. , 2019, Biomaterials.
[39] Sangdun Choi,et al. Recent clinical trends in Toll‐like receptor targeting therapeutics , 2018, Medicinal research reviews.
[40] Thanh Loc Nguyen,et al. Mesoporous Silica as a Versatile Platform for Cancer Immunotherapy , 2018, Advanced materials.
[41] S. Eisenbarth,et al. Dendritic cell subsets in T cell programming: location dictates function , 2018, Nature Reviews Immunology.
[42] R. Coffman,et al. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. , 2018, Cancer discovery.
[43] D. Mooney,et al. Biomaterial-assisted targeted modulation of immune cells in cancer treatment , 2018, Nature Materials.
[44] J. Borst,et al. CD4+ T cell help in cancer immunology and immunotherapy , 2018, Nature Reviews Immunology.
[45] E. Latz,et al. Targeting the NLRP3 inflammasome in inflammatory diseases , 2018, Nature Reviews Drug Discovery.
[46] Kai Yang,et al. Combined local immunostimulatory radioisotope therapy and systemic immune checkpoint blockade imparts potent antitumour responses , 2018, Nature Biomedical Engineering.
[47] W. Loging,et al. Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial , 2018, Clinical Cancer Research.
[48] Rebecca L. Holden,et al. Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability , 2018, Cancer Immunology Research.
[49] Gordon D. Brown,et al. C-type lectins in immunity and homeostasis , 2018, Nature Reviews Immunology.
[50] Aileen W. Li,et al. Injectable, Tough Alginate Cryogels as Cancer Vaccines , 2018, Advanced healthcare materials.
[51] I. Taniuchi. CD4 Helper and CD8 Cytotoxic T Cell Differentiation. , 2018, Annual review of immunology.
[52] M. Gale,et al. RIG-I and Other RNA Sensors in Antiviral Immunity. , 2018, Annual review of immunology.
[53] S. Son,et al. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy , 2018, Science Advances.
[54] Charles H. Yoon,et al. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity , 2018, Science.
[55] J. Jeong,et al. Extra-Large Pore Mesoporous Silica Nanoparticles Enabling Co-Delivery of High Amounts of Protein Antigen and Toll-like Receptor 9 Agonist for Enhanced Cancer Vaccine Efficacy , 2018, ACS central science.
[56] Ö. Türeci,et al. Personalized vaccines for cancer immunotherapy , 2018, Science.
[57] Michael S. Goldberg,et al. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases , 2018, Science Translational Medicine.
[58] R. Dillman,et al. Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses , 2018, Journal of Immunotherapy for Cancer.
[59] Aileen W. Li,et al. A facile approach to enhance antigen response for personalized cancer vaccination , 2018, Nature Materials.
[60] Aileen W. Li,et al. Covalent Conjugation of Peptide Antigen to Mesoporous Silica Rods to Enhance Cellular Responses. , 2018, Bioconjugate chemistry.
[61] Catherine J. Wu,et al. Towards personalized, tumour-specific, therapeutic vaccines for cancer , 2017, Nature Reviews Immunology.
[62] Xun Sun,et al. Lymph node targeting strategies to improve vaccination efficacy , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[63] Ido D. Weiss,et al. Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy , 2017, Nature Communications.
[64] R. A. van den Berg,et al. Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans , 2017, Front. Immunol..
[65] J. Utikal,et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.
[66] Charles H. Yoon,et al. An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.
[67] Tian Zhang,et al. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy , 2017, Nature Nanotechnology.
[68] Xun Sun,et al. Tailoring polymeric hybrid micelles with lymph node targeting ability to improve the potency of cancer vaccines. , 2017, Biomaterials.
[69] R. Förster,et al. Dendritic cell migration in health and disease , 2016, Nature Reviews Immunology.
[70] J. Moon,et al. Designer vaccine nanodiscs for personalized cancer immunotherapy , 2016, Nature materials.
[71] D. Mooney,et al. Designing hydrogels for controlled drug delivery. , 2016, Nature reviews. Materials.
[72] Özlem Türeci,et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.
[73] W. Jiskoot,et al. Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[74] P. Lizotte,et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer , 2015, Nature nanotechnology.
[75] Michael Y. Gerner,et al. In vivo characterization of the physicochemical properties of TLR agonist delivery that enhance vaccine immunogenicity , 2015, Nature Biotechnology.
[76] Scott N. Mueller,et al. Spatiotemporally Distinct Interactions with Dendritic Cell Subsets Facilitates CD4+ and CD8+ T Cell Activation to Localized Viral Infection. , 2015, Immunity.
[77] S. Amigorena. Helping the Help for CD8+ T Cell Responses , 2015, Cell.
[78] Ting-Yu Shih,et al. Injectable cryogel-based whole-cell cancer vaccines , 2015, Nature Communications.
[79] Shinn-Jang Hwang,et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. , 2015, The New England journal of medicine.
[80] J. Castle,et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer , 2015, Nature.
[81] S. Mitragotri,et al. Elasticity of nanoparticles influences their blood circulation, phagocytosis, endocytosis, and targeting. , 2015, ACS nano.
[82] Michael Y. Gerner,et al. Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens. , 2015, Immunity.
[83] Tae Jin Kim,et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients , 2014, Nature Communications.
[84] S. Bertholet,et al. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants , 2014, Proceedings of the National Academy of Sciences.
[85] M. Dhodapkar,et al. Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205 , 2014, Science Translational Medicine.
[86] David J Mooney,et al. Injectable, porous, and cell-responsive gelatin cryogels. , 2014, Biomaterials.
[87] Gregory L. Szeto,et al. Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.
[88] M. Nussenzweig,et al. Intestinal monocytes and macrophages are required for T cell polarization in response to Citrobacter rodentium , 2013, The Journal of experimental medicine.
[89] A. Mackiewicz,et al. Therapeutic gene modified cell based cancer vaccines. , 2013, Gene.
[90] T. Cloughesy,et al. Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma Patients , 2013, Journal of immunotherapy.
[91] Giuseppe Del Giudice,et al. The history of MF59® adjuvant: a phoenix that arose from the ashes , 2013, Expert review of vaccines.
[92] D. Mooney,et al. The efficacy of intracranial PLG-based vaccines is dependent on direct implantation into brain tissue. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[93] D. Venzon,et al. TLR3-Specific Double-Stranded RNA Oligonucleotide Adjuvants Induce Dendritic Cell Cross-Presentation, CTL Responses, and Antiviral Protection , 2011, The Journal of Immunology.
[94] A. Oxenius,et al. Type I IFN Substitutes for T Cell Help during Viral Infections , 2011, The Journal of Immunology.
[95] D. Mooney,et al. Biomaterial-Based Vaccine Induces Regression of Established Intracranial Glioma in Rats , 2011, Pharmaceutical Research.
[96] S. H. van der Burg,et al. Therapeutic cancer vaccines. , 2010, The Journal of clinical investigation.
[97] S. Akira,et al. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.
[98] J. Robinson,et al. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. , 2010, Journal of pharmaceutical sciences.
[99] S. H. van der Burg,et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. , 2009, The New England journal of medicine.
[100] David J Mooney,et al. In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice , 2009, Science Translational Medicine.
[101] K. Sauer,et al. IL-21 Is Required to Control Chronic Viral Infection , 2009, Science.
[102] David J. Mooney,et al. Infection-Mimicking Materials to Program Dendritic Cells In Situ , 2008, Nature materials.
[103] Katrin Schwarz,et al. Nanoparticles target distinct dendritic cell populations according to their size , 2008, European journal of immunology.
[104] Samir Mitragotri,et al. Role of target geometry in phagocytosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[105] C. Figdor,et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. , 2005, Blood.
[106] J. Nemunaitis,et al. GM-CSF gene-transduced tumor vaccines. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[107] R. Steinman,et al. In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.
[108] Kouji Matsushima,et al. Pivotal Role of Dendritic Cell–derived CXCL10 in the Retention of T Helper Cell 1 Lymphocytes in Secondary Lymph Nodes , 2002, The Journal of experimental medicine.
[109] A. Sher,et al. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. , 2000, Immunity.
[110] G. Dranoff,et al. Advances in Therapeutic Cancer Vaccines. , 2016, Advances in immunology.